KGLOW vs NAD+: What Is the Difference?
Both come in unusually large vials, for completely different reasons.
In plain English
KGLOW (or KLOW) holds four compounds in 80 mg: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg.
NAD+ is a coenzyme rather than a peptide, supplied at 500 mg, central to the chemistry of turning food into usable energy in every living cell.
The difference, without the jargon
The shared trait is a big vial; the reasons are unrelated. KGLOW is 80 mg because it contains several ingredients together. NAD+ is 500 mg because it is consumed in bulk by chemical reactions rather than acting as a signal at trace amounts. Both therefore need more liquid than a standard peptide vial, and both catch people who reach for a habitual volume. After that they diverge completely. NAD+ is not made of amino acids, absorbs moisture from the air aggressively, and breaks down in alkaline conditions. KGLOW is a peptide mixture whose main quirk is that its lab report needs to resolve each ingredient with a ratio, because overall purity says nothing about the balance between them.
Common questions
What is the difference between KGLOW and NAD+?
KGLOW is an 80 mg blend of GHK-Cu, BPC-157, TB-500 and KPV. NAD+ is a coenzyme — not a peptide — central to cellular energy metabolism. They share only the fact that both come in larger vials than a typical peptide.
Why do both need more liquid than usual?
Because both have high fill masses, though for different reasons — KGLOW because it holds several ingredients, NAD+ because it is used in bulk quantities. Either way, using a habitual volume gives a far more concentrated solution than intended.
Do they need the same storage?
No. NAD+ needs protection from moisture and from alkaline conditions. KGLOW needs ordinary refrigeration and light protection, plus awareness that its shortest-lived ingredient determines the usable window.
Technical reference below
How they actually differ
Comparing the two: KGLOW is four-component dermal research blend — ghk-cu 50 mg / bpc-157 10 mg / tb-500 10 mg / kpv 10 mg (80 mg total), while NAD+ is dinucleotide coenzyme — not a peptide — different molecular classes with different handling consequences; they call for different primary diluents (bacteriostatic water (0.9% benzyl alcohol) versus sterile or bacteriostatic water); their leading degradation routes differ (copper dissociation from the ghk-cu component at acidic ph or on chelator contact for KGLOW, alkaline hydrolysis for NAD+), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
KGLOW — origin
KGLOW is GLOW with a fourth component added: KPV, a tripeptide (Lys-Pro-Val) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone. The other three amounts are unchanged — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg — with KPV at 10 mg bringing the vial to 80 mg. KPV is studied primarily for anti-inflammatory activity in preclinical models, notably retaining that property of the parent hormone without its pigmentation-related effects.
NAD+ — origin
NAD+ is not a peptide at all, and that single fact governs everything about how it is handled. It is a dinucleotide coenzyme — nicotinamide and adenine linked through a pyrophosphate bridge — present in every living cell and central to redox metabolism. It was first identified in 1906 by Arthur Harden as a small heat-stable factor required for yeast fermentation.
KGLOW research themes
The majority component, with the deepest dermal research literature.
The addition that distinguishes KGLOW — studied for anti-inflammatory activity derived from alpha-MSH without pigmentation effects.
Two complementary tissue-repair mechanisms, unchanged from GLOW.
Adds an inflammation arm to the three repair-focused mechanisms in GLOW.
NAD+ research themes
Sirtuins consume NAD+ as a co-substrate, which links cellular NAD+ availability directly to their activity.
Its canonical role as the central redox carrier of cellular respiration.
PARP enzymes consume NAD+ during DNA damage response, a heavily studied competing demand.
A major driver of current research interest: measured NAD+ levels fall with age across tissues in animal models.
KGLOW handling
- Never reconstitute in acidic diluent — copper dissociation from the GHK-Cu component is the primary risk.
- Keep EDTA and other chelators out of any buffer used with KGLOW.
- Treat colour as data: clear even blue is correct; pale or green is not.
- Protect from light and minimise headspace exposure for the TB-500 component.
- Scale diluent to the 80 mg fill — habitually adding 2 mL as though to a 10 mg vial gives a solution eight times more concentrated than intended.
NAD+ handling
- Allow the sealed vial to reach room temperature before opening — opening a cold vial of hygroscopic material condenses water directly onto it.
- Keep solutions at or below neutral pH; alkaline conditions destroy NAD+ quickly.
- Prepare fresh solutions where concentration accuracy is important rather than relying on stored stock.
- Protect from light at all stages.
Both third-party tested
Every Popular Peptides batch of KGLOW and NAD+ is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
KGLOW reference
Related comparisons
KGLOW and NAD+ are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.